The present disclosure relates generally to prosthetic valves and more specifically to apparatuses, systems, and methods that include conduits having a valve structure therein.
Bioprosthetic heart valves have been developed that attempt to mimic the function and performance of a native valve. Flexible leaflets may be coupled to a relatively rigid frame or other support structure that supports the leaflets and provides dimensional stability when implanted.
The leaflets require some means for securing the leaflets to a support structure. In operation, the leaflets open when the upstream fluid pressure exceeds the downstream fluid pressure and close when the downstream fluid pressure exceeds the upstream fluid pressure. The leaflet free edges of the leaflets coapt under the influence of downstream fluid pressure closing the prosthetic heart valve to prevent downstream blood from flowing retrograde through the prosthetic heart valve.
Prosthetic heart valve durability under the repetitive loads of the leaflets opening and closing is dependent, in part, on the load distribution between the leaflet and the frame or support structure and, specifically, the attachment of the leaflet to the frame. Mechanical failure of the leaflet can arise, for example, at a mounting edge where the flexible leaflet is supported by the relatively rigid frame. The repetitive loads of leaflet opening and closing leads to material failure by fatigue, creep or other mechanism, depending in part on the leaflet material.
Described embodiments are directed to apparatus, system, and methods for valved conduit prostheses.
According to one example (“Example 1”), a valved conduit prosthesis includes a conduit having an exterior surface and an interior surface defining a conduit lumen and a slot therethrough; and at least one leaflet having an external portion coupled to the exterior surface of the conduit and an internal portion arranged within the interior surface of the conduit so as to be operable as a one-way valve, the leaflet defining a valve structure.
According to another example (“Example 2”) further to Example 1, the external portion of the at least one leaflet is coupled to the exterior surface of the conduit by adhesive, thermal bonding, or chemical bonding.
According to another example (“Example 3”) further to any one of Examples 1-2, the conduit is free of sinuses.
According to another example (“Example 4”) further to any one of Examples 1-2, the conduit is free of mechanical coupling.
According to another example (“Example 5”) further to any one of Examples 1-4, the external portion of the at least one leaflet is coupled to the exterior surface of the conduit, and the coupling is sutureless.
According to another example (“Example 6”) further to any one of Examples 1-5, the external portion of the at least one leaflet is coupled to the exterior surface of the conduit by a layer of adhesive film.
According to another example (“Example 7”) further to Example 6, wherein the adhesive film is arranged about a circumference of the conduit.
According to another example (“Example 8”) further to any one of Examples 6-7, further including a flexible film arranged about the circumference of the conduit and the adhesive film.
According to another example (“Example 9”) further to Example 8, the flexible film includes expanded polytetrafluoroethylene (ePTFE) and the adhesive film comprises fluorinated ethylene propylene (FEP).
According to another example (“Example 10”) further to any one of Examples 8-9, further including a support frame coupled to the conduit by the flexible film.
According to another example (“Example 11”) further to Example 10, the support frame is formed of polyether ether ketone (PEEK).
According to another example (“Example 12”) further to any one of Examples 1-11, further including at least one radiopaque marker arranged adjacent to the at least one leaflet on the exterior surface of the conduit.
According to another example (“Example 13”) further to any one of Examples 1-12, the interior surface of the conduit is diametrically constant and free of any macroscopic interruptions.
According to another example (“Example 14”) further to any one of Examples 1-13, the at least one leaflet is positioned within the conduit at a longitudinal location along the length of the conduit, and the conduit is diametrically constant at the longitudinal location where the at least one leaflet is positioned and through adjacent proximal and distal portions of the conduit.
According to one example (“Example 15”), a valved conduit prosthesis includes a conduit having an interior surface, an exterior surface, a proximal portion, and a distal portion; a leaflet attachment portion having an opening between the interior surface and the exterior surface of the conduit, and at least one leaflet having an attachment portion coupled to the exterior surface of the conduit without mechanical alteration of the interior surface or the exterior surface of the conduit to mitigate against thrombus formation within the conduit.
According to another example (“Example 16”) further to any of Examples 1-15, the at least one leaflet includes three leaflets, and the three leaflets are separated from one another within the interior of the conduit by lands.
According to another example (“Example 17”) further to any one of Examples 1-15, the conduit includes lands separating the leaflets at the attachment portion of each of the leaflets to form commissure gaps between the three leaflets within the interior surface of the conduit, wherein the commissure gaps provide a regurgitant flow path when the valve is in the closed position.
According to another example (“Example 18”) further to any one of Examples 15-17, the attachment section is attached to the exterior surface of the conduit by an adhesive, thermal bonding, or chemical bonding.
According to another example (“Example 19”) further to any one of Examples 1-18, the attachment section includes a first portion and a second portion, and the first portion is attached to the proximal portion of the exterior surface of the conduit, and the second portion is attached to the distal portion of the exterior surface of the conduit.
According to another example (“Example 20”) further to any one of Examples 15-19, the leaflet attachment portion is a portion of the conduit, and the leaflet attachment portion is denser than adjacent portions of the conduit.
According to one example (“Example 21”), further to any one of Examples 15-20, the valved conduit prosthesis also includes a directional indicator on the exterior surface of the conduit to indicate the direction of blood flow within the conduit when in the open condition.
According to one example (“Example 22”), a method for reducing thrombus formation arising from the replacement of the native pulmonary valve or of a previously implanted pulmonary valved conduit prosthesis where partial or complete reconstruction of the right ventricular outflow tract and/or main pulmonary artery is desired, the method includes providing a valved conduit prosthesis comprising a synthetic conduit having a distal end, proximal end, an interior, an exterior, and a leaflet attachment portion and at least one flexible synthetic leaflet having a portion external to the conduit and a portion internal to the conduit, wherein the leaflet portion external to the conduit is coupled to the exterior of the conduit at the attachment portion and wherein the attachment portion of the conduit is free of punctures, and surgically implanting the valved conduit prosthesis.
According to one example (“Example 23”), a method for the replacement of the native pulmonary valve or of a previously implanted pulmonary valved conduit prosthesis where partial or complete reconstruction of the right ventricular outflow tract and/or main pulmonary artery is desired, the method includes providing a valved conduit prosthesis comprising a synthetic conduit and at least one flexible synthetic valve leaflet coupled to the synthetic conduit that has been rinsed in saline and has not been pre-clotted, and surgically implanting the valved conduit prosthesis.
According to one example (“Example 24”), a method for the replacement of the native pulmonary valve or of a previously implanted pulmonary valved conduit prosthesis where partial or complete reconstruction of the right ventricular outflow tract and/or main pulmonary artery is desired, the method includes providing a valved conduit prosthesis that has been rinsed in saline and has not been pre-clotted, wherein said valved conduit prosthesis comprises a non-biological conduit and at least one flexible polymeric non-biological valve leaflet attached to the non-biological conduit, identifying the inflow and outflow portions of the valved conduit prosthesis, accessing the intended position with respect to the coronary arteries to assure there is no risk of coronary compression when implanted, optionally trimming the inflow and or outflow conduit, while under moderate tension, to the appropriate length for implantation, and attaching the valved conduit prosthesis.
According to one example (“Example 25”), a packaging insert for a valved conduit prosthesis, the packaging insert includes a support structure configured to fold to form one or more supports and to insert within the valved conduit prosthesis to support one or more leaflets within the valved conduit prosthesis.
According to an example (“Example 26”), a method of treating aortic valve disease by replacing the aortic root, includes providing a valved conduit prosthesis of any of Examples above and surgically implanting the valved conduit prosthesis.
According to an example (“Example 27”), the method of example 26, further comprising identifying an inflow portion and outflow portion of the conduit, accessing the intended position with respect to anatomy, optionally trimming the inflow portion and outflow portion of the conduit to the appropriate length for implantation, optionally outwardly tapering the inflow end or optionally everting and rolling the inflow portion toward the leaflet structure defining a sewing cuff, sectioning the ascending aorta, coupling the inflow portion of the valved conduit prosthesis to the left ventricle adjacent to or in the place of an excised aortic valve, and coupling the outflow portion of the valved conduit prosthesis to the sectioned ascending aorta.
According to an example (“Example 28”), the method of example 27, further comprising coupling coronary arteries to the outflow portion of the conduit 102 and establishing a flow path from the conduit lumen to the coronary arteries.
According to an example (“Example 29”), the method of example 28, further comprising coupling the coronary arteries to a sinus defined by the outflow portion.
According to an example (“Example 30”), further to any of Examples 1-29, wherein the one or more leaflets comprise a composite material including a porous synthetic fluoropolymer membrane defining pores and an elastomer or elastomeric material filling the pores, and optionally TFE-PMVE copolymer comprising from 27 to 32 weight percent perfluoromethyl vinyl ether and respectively from 73 to 68 weight percent tetrafluoroethylene on at least a portion of the composite material, and optionally, the elastomer or elastomeric material comprises a TFE-PMVE copolymer, and optionally, the porous synthetic fluoropolymer membrane is ePTFE.
According to an example (“Example 31”), further to any of Examples 1-30, wherein the conduit has an inflow portion defining an inflow end and an outflow portion defining an outflow end, wherein the at least one leaflet is operable to open to allow flow from the inflow end to pass through the outflow end of the conduit in antegrade flow conditions, and is operable to close to restrict flow from flowing from the outflow end through the inflow end in retrograde flow conditions.
According to an example (“Example 32”), further to any of Examples 1-31, wherein the at least one leaflet comprises a composite material including a porous synthetic fluoropolymer membrane defining pores and an elastomer or elastomeric material filling the pores, and optionally TFE-PMVE copolymer comprising from 27 to 32 weight percent perfluoromethyl vinyl ether and respectively from 73 to 68 weight percent tetrafluoroethylene on at least a portion of the composite material, and optionally, the elastomer or elastomeric material comprises a TFE-PMVE copolymer, and optionally, the porous synthetic fluoropolymer membrane is ePTFE.
According to an example (“Example 33”), further to any of Examples 1-32, wherein the outflow portion defines a sinus adjacent to the at least one leaflet.
According to an example (“Example 34”), further to Example 33, wherein the sinus is operable for the surgical attachment of blood vessels and/or coronary arteries.
According to an example (“Example 35”), further to any one of Examples 1-34, wherein the inflow end defines an outward taper or is operable to be outwardly tapered.
According to an example (“Example 36”), further to any one of Examples 1-34, wherein the inflow portion is operable to be outwardly everted and rolled toward the valve structure defining a sewing cuff.
According to an example (“Example 37”), a valved conduit prosthesis includes a conduit having an interior surface defining a conduit lumen, an exterior surface, a proximal portion, and a distal portion, a leaflet attachment portion having an opening between the interior surface and the exterior surface of the conduit, and at least one leaflet having an attachment section attached to the exterior surface of the conduit, the at least one leaflet defining a valve structure.
According to an example (“Example 38”), further to Example 37, the at least one leaflet includes three leaflets, and the three leaflets are separated from one another within an interior of the conduit by commissure gaps.
According to an example (“Example 39”), further to Example 38, the conduit includes lands separating the leaflets at the attachment section of each of the leaflets to form the commissure gaps between the three leaflets within the interior surface of the conduit.
According to an example (“Example 40”), further to any one of Examples 37-39, the attachment section is attached to the exterior surface of the conduit by an adhesive, thermal bonding, or chemical bonding.
According to an example (“Example 41”), further to any one of Examples 37-40, the leaflet attachment portion is a portion of the conduit and the leaflet attachment portion is denser than remaining portions of the conduit.
According to an example (“Example 42”), further to any one of Examples 37-41, wherein the conduit has an inflow portion defining an inflow end and an outflow portion defining an outflow end, wherein the at least one leaflet is coupled to the conduit are operable to open to allow flow from the inflow end to pass through the outflow end of the conduit in antegrade flow conditions, and are operable to close to restrict flow from flowing from the outflow end through the conduit inflow end in retrograde flow conditions.
According to an example (“Example 43”), further to any one of Examples 37-42, the at least one leaflet comprises a composite material including a porous synthetic fluoropolymer membrane defining pores and an elastomer or elastomeric material filling the pores, and optionally TFE-PMVE copolymer comprising from 27 to 32 weight percent perfluoromethyl vinyl ether and respectively from 73 to 68 weight percent tetrafluoroethylene on at least a portion of the composite material, and optionally, the elastomer or elastomeric material comprises a TFE-PMVE copolymer, and optionally, the porous synthetic fluoropolymer membrane is ePTFE.
The foregoing Examples are just that and should not be read to limit or otherwise narrow the scope of any of the inventive concepts otherwise provided by the instant disclosure.
The accompanying drawings are included to provide a further understanding of the disclosure and are incorporated in and constitute a part of this specification, illustrate embodiments, and together with the description serve to explain the principles of the disclosure.
Persons skilled in the art will readily appreciate that various aspects of the present disclosure can be realized by any number of methods and apparatus configured to perform the intended functions. It should also be noted that the accompanying drawing figures referred to herein are not necessarily drawn to scale, but may be exaggerated to illustrate various aspects of the present disclosure, and in that regard, the drawing figures should not be construed as limiting.
Although the embodiments herein may be described in connection with various principles and beliefs, the described embodiments should not be bound by theory. For example, embodiments are described herein in connection with prosthetic valved conduit prostheses. However, embodiments within the scope of this disclosure can be applied toward any valved conduit prosthesis, valve structure, or mechanism of similar structure and/or function. Furthermore, embodiments within the scope of this disclosure can be applied in non-cardiac applications.
The term “conduit”, as used herein, is defined as a tubular member having a lumen operable to direct fluid therethrough and having a wall that is impermeable to fluid transfer.
The terms “valved conduit” and “valved conduit prosthesis”, as used herein, is used interchangeably and are defined as a conduit with a valve structure that is coupled to and contained within the conduit for use in coronary or vascular procedures.
The term “valve structure”, as used herein, is defined as one or more separate leaflets or a leaflet construct having a plurality of leaflets that are coupled together that function as a one-way valve.
The term “leaflet construct”, as used herein, is defined as a valve structure comprising a plurality of leaflets that are coupled together with a commissure region between each leaflet.
The term “valved conduit assembly”, as used herein, is defined as a valved conduit of a reduced length that may be positioned within a primary conduit.
The term “membrane”, as used herein, refers to a sheet comprising a single material, such as, but not limited to, expanded fluoropolymer.
The term “composite material”, as used herein, refers to a combination of a membrane, such as, but not limited to, expanded fluoropolymer, and an elastomer or elastomeric material, such as, but not limited to, a fluoroelastomer. The elastomer or elastomeric material can be contained within a porous structure of the membrane, coated on one or both surfaces of the membrane, or a combination of coated on and contained within the porous structure of the membrane.
The term “laminate”, as used herein, refers to multiple layers of membrane, composite material, or other materials, such as elastomer or elastomeric material, and combinations thereof.
The term “film”, as used herein, generically refers to one or more of the membrane, composite material, or laminate.
term “biocompatible material”, as used herein, generically refers to any material with biocompatible characteristics including synthetic, such as, but not limited to, a biocompatible polymer, or a biological material, such as, but not limited to, bovine pericardium.
The term “coupled”, as used herein, means joined, connected, attached, adhered, affixed, or bonded, whether directly or indirectly, and whether permanently or temporarily
Embodiments herein include various apparatuses, systems, and methods for a conduit having a valve structure operable as a prosthetic valve that can be used, such as, but not limited to, replace a pulmonary valve and a portion of the corresponding pulmonary artery. The valve structure may include one or more leaflets operable as a one-way valve with the conduit defining a conduit lumen. The leaflet(s) open to permit flow and close to occlude the conduit lumen and prevent flow in response to differential fluid pressure.
Embodiments herein include various apparatuses, systems, and methods for a conduit having a valve structure operable as a prosthetic valve that can be used, such as, but not limited to, replace an aortic valve and a portion of the aorta, such as the ascending aorta. The valve structure may include one or more leaflets operable as a one-way valve with the conduit defining a conduit lumen. The leaflet(s) open to permit flow and close to occlude the conduit lumen and prevent reverse flow in response to differential fluid pressure. The conduit is operable to be surgically coupled to the left atrium at a conduit proximal end and to a portion of the ascending aorta at a conduit distal end with the use of, such as, but not limited to, suture. In other embodiments, the conduit is also operable for the surgical attachment of one or more coronary arteries thereto to establish blood flow thereto.
The valved conduit prosthesis 100 may be used, in a non-limiting example, to replace an aortic valve and at least a portion of the ascending aorta. In one non-limiting example, the valved conduit prosthesis 100 may be indicated for the correction or reconstruction of the aortic root and aortic valve, i.e., aortic root replacement, in pediatric patients. The valved conduit prosthesis 100 may also be indicated for the replacement of previously implanted homografts or valved conduits that have become dysfunctional or insufficient.
The valved conduit prosthesis 100 may be used, in a non-limiting example, as a shunt for connecting of the right ventricle to the pulmonary artery following a Norwood operation, as frequently performed for the treatment of hypoplastic left heart syndrome. In one non-limiting example, the valved conduit prosthesis 100 may be indicated for the correction or reconstruction of the right ventricle outflow tract (RVOT) in pediatric patients. Such reconstruction may be indicated for congenital heart disorders such as tetralogy of Fallot, Truncus Arterious, Dextro-Transposition of the Great Arteries, Pulmonary Atresia of Intact Ventricular Septum, or Aortic Valvular Disease. The valved conduit prosthesis 100 may also be indicated for the replacement of previously implanted homografts or valved conduits that have become dysfunctional or insufficient. In addition, the valved conduit prosthesis 100 may have applications in treating a wider range of heart disorders, including other areas of the heart.
Generally, the term “distal” is used in the disclosure to refer to the outflow end 215 (distal end) or outflow direction of a valved conduit prosthesis 100, and in turn, the term “proximal” is used to refer to the inflow end 213 of a valved conduit prosthesis 100. Antegrade or forward flow is fluid flow from the inflow end 213 to the outflow end 215 and retrograde flow, also referred to as regurgitant flow when leaking through a closed valve structure 104, is fluid flow from the outflow end 215 to the inflow end 213.
In certain embodiments, the interior surface 110 of the conduit 102 is diametrically constant as shown in
As shown in
As noted above with reference to
The adhesive film 216 may be a continuous or discontinuous layer wrapped about a circumference of the conduit 102. The adhesive film 216 may be placed, or wrapped about a circumference of the conduit 102, at a densified portion 604 (discussed with reference to
Coupling or attaching the leaflet(s) to the exterior surface 320 of the conduit 102 by, for example, an adhesive, thermal bonding, or chemical bonding, as shown in
The valved conduit prosthesis 100 also includes a leaflet 106 that extends into the conduit 102 and toward the center 108 of the conduit. As shown in
The leaflet attachment portion 322 may be densified and/or rigidified relative to the rest of the conduit 102 for a particular purpose. By way of example, but not limited thereto, a densified attachment portion 322 may be provided such that the conduit 102 retains its shape at the valve region 350 during handling and use. By way of other examples, but not limited thereto, a densified attachment portion 322 may be provided to provide a smoother surface texture and/or a reduction in porosity so as to prevent flow disturbance and/or prevent tissue or pannus ingrowth. Densification refers to a process of selectively making the material more dense at selected locations, such as by heating and/or pressure and/or imbibing the pores with an elastomer or elastomeric material. In certain embodiments, the conduit 102 is formed from expanded polytetrafluoroethylene (ePTFE). For ePTFE material that may be relatively porous, the densification process will reduce porosity and/or make the area more rigid.
The valved conduit prosthesis 100 may also include a flexible film 326 arranged about the circumference of the conduit 102 and the adhesive film 216. The flexible film 326, in certain embodiments, may include one or more layers of the flexible film 326. The flexible film 326 may be wrapped multiple times about the conduit 102 and the adhesive film 216. The flexible film 326 may be wrapped as necessary to enhance the strength of the conduit 102 and/or the attachment of the leaflet 106 to the conduit 102 and/or for coupling the tabs 542 and/or for sealing the slits 434 or openings 324 from leaking, and/or to hold the two conduits together that are butt-joined at the leaflet 106, such as will be described as a first conduit 102a and a second conduit 102b as shown in
The flexible film 326, for example, enhances longitudinal tensile strength of the conduit 102 by adding column strength to the conduit 102. The flexible film 326, for example, may be used to ensure that the leaflet 106 is secured to the exterior surface 320 of the conduit 102. In certain embodiments and as noted above, the conduit 102 may be ePTFE. Particularly suitable are ePTFE vascular grafts having stretch/elastic behavior as they provide variable length with bend/kink resistance. In this regard, the exterior surface 320 of the conduit 102 can stretch to conform to the anatomy without kinking the interior surface 318 (luminal flow surface) and thus the conduit lumen 122 of the conduit 102. The flexible film 326 may also be ePTFE with the adhesive film 216 being fluorinated ethylene propylene (FEP). By using the flexible film 326 and the adhesive film 216 in combination, the leaflet 106 may be bonded (e.g., thermally) to the conduit 102.
In certain embodiments, the valved conduit prosthesis 100 may also include a support frame 328 coupled to the exterior surface 320 of the conduit 102 by the flexible film 326, or by other means, such as thermal, adhesive, mechanical and frictional means. The support frame 328 can prevent compression, or otherwise reduce compressibility of the conduit 102 and the valve structure 104 resulting from anatomical compression forces and/or handling forces. In addition, the support frame 328, in certain embodiments, is formed of polyether ether ketone (PEEK). In these instances, the support frame 328 is not radiopaque, and therefore, allows a physician to better visualize the location of the leaflet 106 and the leaflet attachment portion 322 as compared if the support frame 328 was formed from other materials that would interfere with visualization. Visualizing the leaflet 106 and/or the leaflet attachment portion 322 may enhance the ability of a physician to accurately locate and place the conduit 102 in a target location. In other instances, the support frame 328 is formed of a radiopaque material as an aid to positioning or locating post-surgical implantation. In other instances, the support frame 328 is a metal, such as stainless steel, which may present a lower profile of the exterior surface 320 of the conduit 102 (e.g., being thinner), as shown in
The support frame 328 may or may not be radiopaque. In certain instances, the valved conduit prosthesis 100 may include one or more radiopaque markers 330 to assist in visualizing the valve region 350 of the conduit 102 post-procedure under fluoroscopic visualization. The one or more radiopaque markers 330 can be arranged adjacent to the leaflet 106 on the exterior surface 320 of the conduit 102. In certain embodiments and as shown in
The slits 434 are separated by a land 112 where two leaflets 106 come into close proximity defining a commissure 116. As noted above, the slits 434 correspond to the number of leaflets (not shown) that are coupled to the conduit 102. The land 112 corresponds to the commissure 116 (shown in
The slits 434 and the lateral cut 438 correspond to the number of leaflets that are coupled to the conduit 102. Similar to
The cutting pattern 440 includes multiple separate slits 434 with the number of slits corresponding to a number of leaflets (not shown) that will be coupled to the conduit 102. The cutting pattern 440 also includes a lateral cut 438 that is also a cut in the conduit 102 that allows for the conduit 102 to be cut into two conduit components for assembly as shown in
As noted above, the slits 434 and the lateral cut 438 correspond to the number of leaflets that will be coupled to the conduit 102. Similar to
In certain embodiments, the leaflet 106 includes alignment tabs 544, which are tabs 544 that are adjacent to the leaflet free edge. The alignment tabs 544 are formed in the same manner as the tabs 542. The alignment tabs 544, when present in the leaflet 106, are used to interface with the conduit 102 to assist in aligning the leaflet 106 at the commissure 116 for attachment to the conduit 102.
The leaflet 106 is aligned with a slit 434 in the conduit 102. As noted above, multiple leaflets 106 may be coupled to the conduit 102. For ease of illustration,
Once the leaflet 106 is aligned with the slit 434, the tabs 542 may be folded onto the exterior surface 306 of the conduit 102. As shown in
As shown in
The valved conduit prostheses discussed herein are used to replace diseased anatomy in a surgical operation. Prior to implantation, the valved conduit prosthesis may be rinsed in saline and does not require pre-clotting. In accordance with one method of treatment, the valved conduit prosthesis is used as a replacement for an aortic valve and a portion of the ascending aorta, such as in an aortic root replacement. Implanting the valved conduit prosthesis includes identifying the inflow and outflow portions of the conduit, accessing the intended position with respect to the anatomy, and optionally trimming the inflow and or outflow conduit, while under moderate tension, to the appropriate length for implantation. The ascending aorta is sectioned and the inflow portion and/or inflow end of the valved conduit prosthesis is sutured or otherwise coupled to the left ventricle adjacent to or in the place of an excised aortic valve. The outflow portion and/or the outflow end of the valved conduit prosthesis is sutured to the sectioned ascending aorta. Coronary arteries are allowed to remain on the ascending aorta or they may be sutured to the outflow portion of the conduit and a flow path is provided from the conduit lumen to the coronary arteries.
In accordance with another method of treatment, the valved conduit prosthesis 100 may be a replacement of the native pulmonary valve or of a previously implanted pulmonary valved conduit prosthesis where partial or complete reconstruction of the right ventricular outflow tract and/or main pulmonary artery is desired. In certain instances, implantation of the valved conduit prosthesis includes identifying the inflow and outflow portions of the conduit, accessing the intended position with respect to the coronary arteries to assure there is no risk of coronary compression when implanted, and optionally trimming the inflow and or outflow conduit, while under moderate tension, to the appropriate length for implantation.
In accordance with another method of treating aortic valve disease by replacing the aortic root of a patient, the method comprises the steps of providing a valved conduit prosthesis 100 in accordance with embodiments herein and surgically implanting the valved conduit prosthesis 100, as shown in
The expanded fluoropolymer membrane can comprise any suitable microstructure, such as pores, for achieving the desired leaflet performance. Other biocompatible polymers which can be suitable for use in leaflet include but are not limited to the groups of urethanes, silicones (organopolysiloxanes), copolymers of silicon-urethane, styrene/isobutylene copolymers, polyisobutylene, polyethylene-co-poly(vinyl acetate), polyester copolymers, nylon copolymers, fluorinated hydrocarbon polymers and copolymers or mixtures of each of the foregoing.
In various examples, any of the leaflet 106 described herein (e.g., leaflet construct) may be formed of a biocompatible, synthetic material (e.g., including ePTFE and ePTFE composites, or other materials as desired). Other biocompatible polymers which can be suitable for use in synthetic leaflets include but are not limited to the groups of urethanes, silicones (organopolysiloxanes), copolymers of silicon-urethane, styrene/isobutylene copolymers, polyisobutylene, polyethylene-co-poly(vinyl acetate), polyester copolymers, nylon copolymers, fluorinated hydrocarbon polymers and copolymers or mixtures of each of the foregoing.
In other examples, such leaflet construct is formed of a natural material, such as repurposed tissue, including bovine tissue, porcine tissue, or the like.
As The term “elastomer” refers to a polymer or a mixture of polymers that has the ability to be stretched to at least 1.3 times its original length and to retract rapidly to approximately its original length when released.
The term “elastomeric material” refers to a polymer or a mixture of polymers that displays stretch and recovery properties similar to an elastomer, although not necessarily to the same degree of stretch and/or recovery.
The term “non-elastomeric material” refers to a polymer or a mixture of polymers that displays stretch and recovery properties not similar to either an elastomer or elastomeric material, that is, considered not an elastomer or elastomeric material as is generally known.
In accordance with embodiments herein, the leaflet 106 comprises a composite material having at least one porous synthetic polymer membrane layer having a plurality of pores and/or spaces and an elastomer and/or an elastomeric material and/or a non-elastomeric material filling the pores and/or spaces of the at least one synthetic polymer membrane layer. In accordance with other examples, the leaflet 106 further comprises a layer of an elastomer and/or an elastomeric material and/or a non-elastomeric material on the composite material. In accordance with examples, the composite material comprises porous synthetic polymer membrane by weight in a range of 10% to 90%.
An example of a porous synthetic polymer membrane includes expanded fluoropolymer membrane having a node and fibril structure defining the pores and/or spaces. In some examples, the expanded fluoropolymer membrane is expanded polytetrafluoroethylene (ePTFE) membrane. Another example of porous synthetic polymer membrane includes microporous polyethylene membrane.
Examples of an elastomer and/or an elastomeric material and/or a non-elastomeric material include, but are not limited to, copolymers of tetrafluoroethylene and perfluoromethyl vinyl ether (TFE/PMVE copolymer), (per)fluoroalkylvinylethers (PAVE), urethanes, silicones (organopolysiloxanes), copolymers of silicon-urethane, styrene/isobutylene copolymers, polyisobutylene, polyethylene-co-poly(vinyl acetate), polyester copolymers, nylon copolymers, fluorinated hydrocarbon polymers and copolymers or mixtures of each of the foregoing. In some examples, the TFE/PMVE copolymer is an elastomer comprising between 60 and 20 weight percent tetrafluoroethylene and respectively between 40 and 80 weight percent perfluoromethyl vinyl ether. In some examples, the TFE/PMVE copolymer is an elastomeric material comprising between 67 and 61 weight percent tetrafluoroethylene and respectively between 33 and 39 weight percent perfluoromethyl vinyl ether. In some examples, the TFE/PMVE copolymer is a non-elastomeric material comprising between 73 and 68 weight percent tetrafluoroethylene and respectively between 27 and 32 weight percent perfluoromethyl vinyl ether. The TFE and PMVE components of the TFE-PMVE copolymer are presented in wt %. For reference, the wt % of PMVE of 40, 33-39, and 27-32 corresponds to a mol % of 29, 23-28, and 18-22, respectively.
In some examples, the TFE-PMVE copolymer exhibits elastomer, elastomeric, and/or non-elastomeric properties.
In some examples, the composite material further comprises a layer or coating of TFE-PMVE copolymer comprising from 73 to 68 weight percent tetrafluoroethylene and respectively from 27 to 32 weight percent perfluoromethyl vinyl ether.
In some examples, the leaflet the leaflet 106 is an expanded polytetrafluoroethylene (ePTFE) membrane having been imbibed with TFE-PMVE copolymer comprising from 60 to 20 weight percent tetrafluoroethylene and respectively from 40 to 80 weight percent perfluoromethyl vinyl ether, the leaflet 106 further including a coating of TFE-PMVE copolymer comprising from 73 to 68 weight percent tetrafluoroethylene and respectively 27 to 32 weight percent perfluoromethyl vinyl ether on the blood-contacting surfaces.
As discussed above, the elastomer and/or an elastomeric material and/or a non-elastomeric material may be combined with the expanded fluoropolymer membrane such that the elastomer and/or the elastomeric material and/or the non-elastomeric material occupies substantially all of the void space or pores within the expanded fluoropolymer membrane.
Although some examples of suitable leaflet materials have been provided, the foregoing examples are not meant to be read in a limiting sense, and additional or alternative materials are contemplated.
Inventive features of this disclosure have been described above both generically and with regard to specific embodiments. It will be apparent to those skilled in the art that various modifications and variations can be made in the embodiments without departing from the scope of the disclosure. Thus, it is intended that the embodiments cover the modifications and variations of this disclosure provided they come within the scope of the appended claims and their equivalents.
This application is a national phase application of PCT Application No. PCT/US2021/028814, internationally filed on Apr. 23, 2021, which claims the benefit of U.S. Provisional Application No. 63/015,383, filed Apr. 24, 2020, and also claims the benefit of U.S. Provisional Application No. 63/014,124, filed Apr. 23, 2020, which are herein incorporated by reference in their entireties for all purposes.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2021/028814 | 4/23/2021 | WO |
Number | Date | Country | |
---|---|---|---|
63015373 | Apr 2020 | US | |
63014124 | Apr 2020 | US |